Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W D Weaver

Showing results (141-150 of 165) with videos related to

Pageof 17
Sort By:
JAMA|March 13, 1996
Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigatorsW D Weaver, H D White, R G Wilcox, et al.
Circulation|March 14, 1998
Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-IK W Mahaffey, C B Granger, M A Sloan, et al.
American Heart Journal|September 1, 1999
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary ArteriesK W Mahaffey, C B Granger, M A Sloan, et al.
European Heart Journal|April 2, 2002
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarctionF Zijlstra, A Patel, M Jones, et al.
American Heart Journal|September 29, 1999
Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT InvestigatorsA Y Fung, G Lorch, P A Cambier, et al.
Lancet (London, England)|July 6, 2000
Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trialW D Weaver, M A Reisman, J J Griffin, et al.
The American Journal of Cardiology|November 24, 1999
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B InvestigatorsC M Gibson, C P Cannon, S A Murphy, et al.
The American Journal of Cardiology|April 6, 1999
Combined historical and electrocardiographic timing of acute anterior and inferior myocardial infarcts for prediction of reperfusion achievable size limitationK E Corey, C Maynard, O Pahlm, et al.
The American Journal of Cardiology|May 30, 1998
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary ArteriesJ Hochrein, F Sun, K S Pieper, et al.
Annals of Internal Medicine|October 6, 1997
Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrumentH P Selker, J L Griffith, J R Beshansky, et al.
Pageof 17

Showing results (141-150 of 165) with videos related to

Sort By:
Pageof 17
JAMA|March 13, 1996
Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigatorsW D Weaver, H D White, R G Wilcox, et al.
Circulation|March 14, 1998
Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-IK W Mahaffey, C B Granger, M A Sloan, et al.
American Heart Journal|September 1, 1999
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary ArteriesK W Mahaffey, C B Granger, M A Sloan, et al.
European Heart Journal|April 2, 2002
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarctionF Zijlstra, A Patel, M Jones, et al.
American Heart Journal|September 29, 1999
Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT InvestigatorsA Y Fung, G Lorch, P A Cambier, et al.
Lancet (London, England)|July 6, 2000
Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trialW D Weaver, M A Reisman, J J Griffin, et al.
The American Journal of Cardiology|November 24, 1999
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B InvestigatorsC M Gibson, C P Cannon, S A Murphy, et al.
The American Journal of Cardiology|April 6, 1999
Combined historical and electrocardiographic timing of acute anterior and inferior myocardial infarcts for prediction of reperfusion achievable size limitationK E Corey, C Maynard, O Pahlm, et al.
The American Journal of Cardiology|May 30, 1998
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary ArteriesJ Hochrein, F Sun, K S Pieper, et al.
Annals of Internal Medicine|October 6, 1997
Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrumentH P Selker, J L Griffith, J R Beshansky, et al.
Pageof 17